<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9598">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736034</url>
  </required_header>
  <id_info>
    <org_study_id>SharpPS™-Gold 001</org_study_id>
    <nct_id>NCT00736034</nct_id>
  </id_info>
  <brief_title>The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment</brief_title>
  <official_title>A Single-Center, Open-Label Study to Assess the Efficacy of SharpPS™-Gold in Elderly Subjects With Memory Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enzymotec</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to
      improve cognitive performance in elderly subjects with memory impairment.

      This study is a single-center, open-label 15 weeks duration trial to assess efficacy of
      Phosphatidylserine-Omega3 in elderly subjects with memory impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Neuropsychological Computerized Test</measure>
    <time_frame>baseline, 15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition &amp; recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C)Scale</measure>
    <time_frame>15 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician's global impression of change. Global improvement score ranges from 1 = &quot;Very much improved&quot;, through 4 = &quot;No change&quot;, to 7 = &quot;Very much worse&quot;. Participants who experienced an improvement (scores 1, 2 or 3) were classified as improved over the treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Memory Impairment</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Phosphatidylserine-Omega3 (SharpPS™-Gold)</intervention_name>
    <description>Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Ability to give written informed consent

          2. Age: 90≥ years ≥65

          3. Gender: male and female.

          4. Clinical Dementia Rating Scale (CDR) ≤ 0.5

          5. Mini-Mental State Examination (MMSE) ≥ 26

          6. Memory test performance within or below the mean established for adults, with maximum
             of four neuropsychological subtests of the computerized test scored as 1.5 SD above
             the mean

          7. Language: Subjects must be able to read, write and speak Hebrew.

          8. Ability to perform tests and interviews.

        EXCLUSION CRITERIA

          1. Evidence of delirium, confusion, or other disturbances of consciousness.

          2. Any Neurological disorder that could produce cognitive deterioration. Such disorders
             include AD, Parkinson's disease, stroke, intracranial hemorrhage, local brain lesions
             including tumors, and normal pressure hydrocephalus

          3. History of any infective or inflammatory brain disease including those of viral,
             fungal, or syphilitic etiologies.

          4. Head injury immediately preceding cognitive deterioration.

          5. Current psychiatric diagnosis according to DSM IV criteria of depression, mania, or
             any other major psychiatric disorder, or evidence of depression as determined by the
             Geriatric Depression Scale (GDS15) score of 5 or more.

          6. Current diagnosis or history of alcoholism or drug dependence.

          7. Any medical disorder that could produce cognitive deterioration including renal,
             respiratory, cardiac and hepatic disease, diabetes mellitus, endocrine, metabolic or
             hematological disturbances unless well controlled, and malignancy not in remission
             for more than two years.

          8. Use of psychotropic drug or any other drug or supplement that may significantly
             affect cognitive functioning during the month prior to psychometric testing.

          9. Use of any experimental medication within 1 month prior to screening or as
             concomitant medications.

         10. History of hypersensitivity or allergy to fish or fish oil.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Vakhapova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sourasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center, Neurology department</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <lastchanged_date>March 26, 2010</lastchanged_date>
  <firstreceived_date>August 14, 2008</firstreceived_date>
  <firstreceived_results_date>March 4, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Inbal Eyal M.Sc</name_title>
    <organization>Enzymotec</organization>
  </responsible_party>
  <keyword>Age Associated Memory Impairment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through advertisements in senior citizens' homes, hospitals, and newspapers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PS-Omega3</title>
          <description>Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PS-Omega3</title>
          <description>Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="75.29" spread="7.09"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropsychological Computerized Test</title>
        <description>The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition &amp; recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).</description>
        <time_frame>baseline, 15 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>PS-Omega3</title>
            <description>Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Neuropsychological Computerized Test</title>
            <description>The computerized neuropsychological assessment software consists of seven separate tasks: symbol spotting, pattern identification, pattern recall, digit-symbol substitution, digits span forward, digits span backward and delayed pattern recall. Based on the results obtained in the single tasks, eight cognitive composite scores are calculated including focused attention, sustained attention, memory recognition &amp; recall, visuospatial learning, spatial short term memory, executive functions and mental flexibility.The total score range is from 0 to 100 points(0 is worse, 100 is best).</description>
            <units>Points on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Focused Attention</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.16" spread="12.39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sustained Attention</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.38" spread="11.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Memory - Recognition</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.88" spread="9.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Memory - Recall</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.50" spread="12.14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>VisuoSpatial Learning</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.83" spread="24.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spatial Short Term Memory</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.16" spread="29.88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Executive Functions</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.88" spread="19.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mental Flexibility</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.88" spread="20.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Change (CGI-C)Scale</title>
        <description>The Clinical Global Impression of Change (CGI-C)scale is designed to record the clinician’s global impression of change. Global improvement score ranges from 1 = “Very much improved”, through 4 = “No change”, to 7 = “Very much worse”. Participants who experienced an improvement (scores 1, 2 or 3) were classified as improved over the treatment period.</description>
        <time_frame>15 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PS-Omega3</title>
          <description>Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <description>Not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. V. Vakhapova</name_or_title>
      <organization>Sourazky Tel-Aviv Medical Center</organization>
      <phone>972-3-6973698</phone>
      <email>vedanicek@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
